Iceland· IS-EU/1/13/875/005
Deltyba
A delamanid product containing delamanidum inn, registered in Iceland by Otsuka Novel Products GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Delamanid is registered in 12 of 19 countries.
Countries holding a registration under ATC J04AK06 (delamanid), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Delamanid · ATC J04AK06
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Delamanidum INN
- Manufacturer
- Otsuka Novel Products GmbH
- Country
- Iceland (IS)
- ATC code
- J04AK06
- ATC class
- Delamanid
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Delamanid in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDELTYBAOtsuka Novel Product GmbH, München
- SwedenDeltyba 25 mg Dispergerbar tablettOtsuka Novel Products GmbH
- IrelandDeltybaOtsuka Novel Products GmbH
- NetherlandsDeltyba 25 mg, dispergeerbare tablettenOtsuka Novel Products GmbH
- PolandDeltybaOtsuka Novel Products GmbH
- BelgiumDeltyba 25 mgOtsuka Novel Products
- FinlandDeltybaOtsuka Novel Products GmbH
- FranceDELTYBA 25 mg, comprimés dispersiblesOTSUKA NOVEL PRODUCTS (ALLEMAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Deltyba
- Norway · Deltyba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2219f933-e0a2-44d2-859d-692192da6e0d GET /v1/drugs/2219f933-e0a2-44d2-859d-692192da6e0d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dreifitafla",
"source": "lyfjastofnun",
"atc_raw": "J04AK06",
"marketed": false,
"strength": "25 mg",
"ma_number": "EU/1/13/875/005",
"substance": "Delamanidum INN",
"other_info": "Ávísun lyfsins er bundin við smitsjúkdómalækna og lungnalækna með reynslu af meðferð sjúklinga með fjölónæma berkla.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44455"
}See everything about delamanid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.